For many pharmaceutical, medical device and bio-pharmaceutical organisations, development of a clear vision of how the various automation technologies inter-relate presents a significant challenge.
This is partly because there is significant overlap in functionality between Manufacturing Execution Systems (MES), systems to support Process Analytic Technology (PAT), Electronic Batch Record (EBR) systems, and a host of lower level plant automation technologies. The challenge is exacerbated because of the complexity of the offering provided by most vendors of such technologies, and by constraints caused by corporate policies.
BSM works with life science companies to develop current and proposed future automation systems architectures, which clearly delineate the various systems and vendors and which can be used as a blueprint for future automation projects.
BSM uses elements of the ANSI ISA-S95 and S-88 standards, in conjunction with an MES/EBR vision developed from the MESA framework, to provide a reference model against which current and future systems can be mapped.
Completed architecture maps can then be used a basis for plant and corporate level technology presentations, as well as the starting point for future technology selection projects.
Sean Jackson will respond to your query.